builderall

CONFERENCE INFORMATION

Conference Description

This program focuses on the dissemination of emerging clinical evidence and comprehensive oral and intravenous pharmacotherapy management strategies across a variety of specialties. The exponential growth of specialty therapies, coupled with increasing utilization of multiple lines of treatment, calls for close oversight of an expanding and increasingly complex therapeutic landscape. Concurrent advances in diagnostics and the rapid evolution of precision medicine continue to shape individualized treatment selection and sequencing.

Given the magnitude and pace of emerging scientific evidence, it is essential that pharmacists are equipped with cutting-edge, evidence-based education to support optimal therapy options. This summit also emphasizes the identification of best practices that address the unique challenges and opportunities related to patient access while driving operational efficiency and value for provider organizations.

By design, this program convenes subject matter experts and local leaders to highlight both clinical and practical considerations related to emerging specialty pharmaceuticals across oncology and malignant hematology, as well as breakthrough therapeutic advancements in other disease states, including neurology, cardiology, and endocrinology. The summit content will underscore the critical role of pharmacists in optimizing patient adherence, as well as best practices related to the utilization of biosimilars, 505(b)(2) products, intravenous versus subcutaneous formulations, and bispecific therapies in both hematologic malignancies and solid tumors. Additional discussions will address key practice considerations, including navigating payer authorizations, managing drug utilization, and evaluating practice expansion opportunities driven by the continued growth of specialty infusion. Throughout, these sessions will highlight strategies across the ecosystem of stakeholders that collectively establish access to specialty pharmaceuticals.

Conference Description

This conference is the premier destination for oncology pharmacy professionals and interdisciplinary oncology team members to engage in the exchange of current and emerging cancer pharmacotherapies, precision medicine advances, and innovative practice management strategies. As the oncology treatment landscape evolves rapidly, this activity will promote collaboration among oncology pharmacists, clinicians, and practice leaders to enhance the delivery of evidence-based, patient-centered care.

Designed to support informed decision-making and improve patient outcomes, the program will provide a comprehensive review of the latest developments in oncology therapeutics, molecular diagnostics, therapy monitoring, and supportive care. Sessions will also address strategies for navigating financial and operational challenges in practice, optimizing value-based care, and integrating cutting-edge technologies into pharmacy workflows. This educational opportunity will empower pharmacists and the broader care team to contribute meaningfully to cancer care optimization and patient safety.

Join us as we unite the oncology pharmacy community of South Florida, along with other industry stakeholders, in our journey to continue to drive transformative possibilities in cancer care. It is in our collective efforts that lies the opportunity to elevate cancer care delivery and patient outcomes.

Target Audience & Expected Audience

This activity is designed for oncology pharmacists, pharmacy residents and students with an interest in oncology, and pharmacy technicians. The conference also welcomes the broader multidisciplinary oncology care team, including physicians, advanced practice providers (NPs and PAs), nurses, and practice administrators who collaborate in delivering high-quality cancer care.

Expected attendance: 75–100 oncology pharmacists and oncology-focused professionals.

Learner Objectives

Upon completion of this conference, participants will be able to:

  • At the conclusion of this activity, participants should be better able to:

  • Describe emerging oncology pharmacotherapy options and their mechanisms of action to support evidence-based treatment selection.

  • Evaluate patient- and drug-specific considerations for managing, monitoring, and adjusting oncology therapies to mitigate adverse effects and enhance therapeutic benefit.

  • Apply principles of precision medicine and molecular diagnostics to guide individualized cancer pharmacotherapy decision-making.

  • Develop strategies to improve adherence, optimize outcomes, and support transitions of care in oncology pharmacy practice.

  • Identify practice management innovations and operational efficiencies that enhance the value and sustainability of cancer care delivery.

Target Audience & Expected Attendance

This continuing pharmacy education activity is designed for pharmacists and pharmacy technicians who provide, manage, or support specialty pharmacotherapy services in a variety of settings, including hospital, clinical, community, and specialty pharmacy practice. The content is appropriate for those involved in patient care, formulary management, and clinical decision-making related to specialty and complex therapies.

Expected attendance: 50–75 participants.

Learner Objectives

At the conclusion of this activity, learners should be better able to:

  • Evaluate emerging specialty pharmacotherapy options and determine their relevance to patient-specific treatment plans.

  • Apply evidence-based strategies for therapy management, monitoring, and adherence support in complex disease states.

  • Implement validated tools and processes to optimize patient adherence and therapeutic outcomes.

  • Assess opportunities to integrate biosimilars, 505(b)(2) products, and innovative therapies to enhance clinical and operational efficiency.

  • Develop collaborative strategies among pharmacists, patients, payers, and manufacturers to improve access and value in specialty pharmacy practice.